We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Adaptive Biotechnologies Corporation is a biotechnology business with stocks listed in the US. Adaptive Biotechnologies shares (ADPT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$39.75 – an increase of 4.3% over the previous week. Here's how to invest if you're based in Australia.
How to buy shares in Adaptive Biotechnologies
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Adaptive Biotechnologies. Find the share by name or ticker symbol: ADPT. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Adaptive Biotechnologies reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$33.69, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Adaptive Biotechnologies, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Adaptive Biotechnologies. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
- Adaptive Biotechnologies key stats
- Compare share trading platforms
- Is Adaptive Biotechnologies stock a buy or sell?
- Adaptive Biotechnologies performance over time
- Can I short Adaptive Biotechnologies shares?
- Adaptive Biotechnologies's financials
- How volatile are Adaptive Biotechnologies shares?
- Does Adaptive Biotechnologies pay a dividend?
- Other common questions
Adaptive Biotechnologies stock price (NASDAQ:ADPT)Use our graph to track the performance of ADPT stocks over time.
Adaptive Biotechnologies shares at a glance
|52-week range||US$29.735 - US$71.25|
|50-day moving average||US$35.312|
|200-day moving average||US$38.4321|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||US$-1.244|
Where to buy Adaptive Biotechnologies stock
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Is it a good time to buy Adaptive Biotechnologies stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Considering buying Adaptive Biotechnologies shares?Before you consider Adaptive Biotechnologies, you'll want to hear this.
Ticker Nerd uses advanced software to track hundreds of signals and data points to find stocks before they blow up. You can get the next two hot stocks they find sent to your inbox for free.
Show me how
Adaptive Biotechnologies price performance over time
|1 week (2021-09-09)||3.65%|
|1 month (2021-08-19)||32.41%|
|3 months (2021-06-18)||0.76%|
|6 months (2021-03-19)||-5.11%|
|1 year (2020-09-18)||-14.24%|
|2 years (2019-09-19)||1.87%|
Stocks similar to Adaptive Biotechnologies
Adaptive Biotechnologies financials
|Revenue TTM||US$133.4 million|
|Gross profit TTM||US$-40,220,000|
|Return on assets TTM||-11.41%|
|Return on equity TTM||-28%|
|Market capitalisation||US$5.6 billion|
TTM: trailing 12 months
Shorting Adaptive Biotechnologies shares
There are currently 4.0 million Adaptive Biotechnologies shares held short by investors – that's known as Adaptive Biotechnologies's "short interest". This figure is 8.4% down from 4.4 million last month.
There are a few different ways that this level of interest in shorting Adaptive Biotechnologies shares can be evaluated.
Adaptive Biotechnologies's "short interest ratio" (SIR)
Adaptive Biotechnologies's "short interest ratio" (SIR) is the quantity of Adaptive Biotechnologies shares currently shorted divided by the average quantity of Adaptive Biotechnologies shares traded daily (recently around 568752.98295455). Adaptive Biotechnologies's SIR currently stands at 7.04. In other words for every 100,000 Adaptive Biotechnologies shares traded daily on the market, roughly 7040 shares are currently held short.
However Adaptive Biotechnologies's short interest can also be evaluated against the total number of Adaptive Biotechnologies shares, or, against the total number of tradable Adaptive Biotechnologies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Adaptive Biotechnologies's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Adaptive Biotechnologies shares in existence, roughly 30 shares are currently held short) or 0.043% of the tradable shares (for every 100,000 tradable Adaptive Biotechnologies shares, roughly 43 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Adaptive Biotechnologies.
Find out more about how you can short Adaptive Biotechnologies stock.
Adaptive Biotechnologies share dividends
We're not expecting Adaptive Biotechnologies to pay a dividend over the next 12 months.
Adaptive Biotechnologies share price volatility
Over the last 12 months, Adaptive Biotechnologies's shares have ranged in value from as little as US$29.735 up to US$71.25. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adaptive Biotechnologies's is 0.2561. This would suggest that Adaptive Biotechnologies's shares are less volatile than average (for this exchange).
Adaptive Biotechnologies overview
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. It also has a research collaboration with Curebase, Inc. to enhance patient participation in clinical studies. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Adaptive Biotechnologies in the news
Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth
Chief Scientific Officer Of Adaptive Biotechnologies Trades $505.90 Thousand In Company Stock
Adaptive Biotechnologies to Present New SARS-CoV-2 Data from its Immune Medicine Platform During IDWeek 2021
Frequently asked questions
More guides on Finder
Why is the Telstra share price running higher today?
Shares in the telecoms operator have jumped nearly 40% over the last 12 months.
How to buy IRON Titanium Token (TITAN) in Australia
This guide will show you step-by-step instructions on how to buy the IRON Titanium Token (TITAN) token as well as a list of exchanges you can trade it on.
How to buy Wabi (WABI) in Australia
This guide will show you step-by-step instructions on how to buy the Wabi (WABI) token as well as a list of exchanges you can trade it on.
How to buy Cindicator (CND) in Australia
This guide will show you step-by-step instructions on how to buy the Cindicator (CND) token as well as a list of exchanges you can trade it on.
How to buy MonaCoin (MONA) in Australia
This guide will show you step-by-step instructions on how to buy the MonaCoin (MONA) token as well as a list of exchanges you can trade it on.
How to buy Bluzelle (BLZ) in Australia
This guide will show you step-by-step instructions on how to buy the Bluzelle (BLZ) token as well as a list of exchanges you can trade it on.
How to buy Whitecoin (XWC) in Australia
This guide will show you step-by-step instructions on how to buy the Whitecoin (XWC) token as well as a list of exchanges you can trade it on.
How to buy Storj (STORJ) in Australia
This guide will show you step-by-step instructions on how to buy the Storj (STORJ) token as well as a list of exchanges you can trade it on.
Will Qantas shares jump as it locks in travel dates to Fiji, the UK and the US?
Despite the good news, Qantas shares closed flat following the announcement, but that could change in the coming weeks.
Why is the Pilbara Minerals share price zooming today?
Shares in the lithium producer are up five-fold over the last 12 months.
Ask an Expert